Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged subcutaneous bortezomib plus dexamethasone in relapsed/refractory multiple myeloma
2013-000432-10Phase 2Completed
- Sponsor
- HOVON
- Start
- Mar 2013
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in multiple myeloma (MM), sponsored by HOVON. Primary endpoint: Time to progression. Started Mar 2013; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-000432-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000432-10.